Navigation Links
Quest Diagnostics Reports Second Quarter 2013 Financial Results
Date:7/18/2013

mained available under the Company's share repurchase authorizations.7)

On April 9, 2013, the Company completed the sale of its HemoCue diagnostic products business.  As a result, income from discontinued operations, net of taxes for the three and six months ended June 30, 2013, include a gain of $13.3 million associated with the sale of HemoCue.  In addition, income from discontinued operations, net of taxes for the six months ended June 30, 2013, includes discrete tax benefits of $19.8 million associated with favorable resolution of certain tax contingencies related to our NID business, which was wound down in 2006.8)

The outlook for adjusted diluted earnings per common share represents management's estimates for the full year 2013 before the impact of the restructuring and integration charges. These measures are presented because management believes they are useful adjuncts to the corresponding amounts determined under accounting principles generally accepted in the United States since they are meaningful to evaluate the Company's ongoing operating performance and are on a basis consistent with previous estimates of diluted earnings per common share. Adjusted diluted earnings per common share is not a measure of financial performance under accounting principles generally accepted in the United States and should not be considered as an alternative to the corresponding amount determined under accounting principles generally accepted in the United States. The following table reconciles our 2013 outlook, on an adjusted basis, to the corresponding amounts determined under accounting principles generally accepted in the United States. The outlook, on an adjusted basis, excludes the impact of the restructuring and integration charges.  Outlook for 2013 Before Special ItemsRestructuringandIntegrationChargesAs Reported(a)As AdjustedDiluted earnings per common share

$4.11 - $4.26$0.24$4.35 - $4.50 (a)

Repres
'/>"/>

SOURCE Quest Diagnostics Incorporated
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. Quest Diagnostics CE Marks Simplexa™ Test for Cytomegalovirus for Sale in Europe
2. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
3. A 50-year quest to isolate the thermoelectric effect is now over: Magnon drag unveiled
4. Survey Reveals Paternity Questions Loom for More Than One in 10 Americans
5. S.E.D. Labs to be Acquired by Quest Diagnostics
6. Quest Diagnostics STRATIFY JCV™ First FDA Market Authorized Antibody-based Blood Test to Help Stratify PML Risk in Multiple Sclerosis Patients
7. Quest Diagnostics Reports Fourth Quarter 2011 Financial Results; Provides Guidance for 2012
8. Questcor Pharmaceuticals to Present at the Leerink Swann Global Healthcare Conference on February 16, 2012
9. Mars, Incorporated Answers Question: How Does Feeding People and Pets Nurture Science and Discovery? At TEDMED 2012
10. Quest Diagnostics Announces C9orf72 Genetic Test for ALS (Lou Gehrigs Disease)
11. Questcor Pharmaceuticals Expands Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... N.J. , June 1, 2015  Novartis ... clinical study of CTL019, an investigational chimeric antigen ... potential in the treatment of specific types of ... conducted by the University of Pennsylvania,s Perelman School ... refractory (r/r) diffuse large B-cell lymphoma (DLBCL) and ...
(Date:6/1/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/9kv3rl/global ... "Global Bioinformatics Market 2015-2019" report to their ... bioinformatics market to grow at a CAGR of ... a field of science that includes computational analysis ... in DNA form and protein sequences in various ...
(Date:6/1/2015)... Ill. , ROCHESTER, Minn. ... June 1, 2015 Baxter Ventures, the venture ... the Mayo Clinic and Velocity Pharmaceutical Development, LLC ("VPD") ... Vitesse is a unique collaboration model initiated by Baxter ... protein-based therapeutics in the areas of immunology, hematology, and ...
(Date:6/1/2015)... 2015   Epic Sciences, Inc. , a private ... to personalize and advance the treatment and management of ... credit under its existing credit facility with Silicon ... available capacity of the facility from $5 million to ... months to April 1, 2019.  The availability of additional ...
Breaking Biology Technology:Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 2Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 3Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 4Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 5Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 6Global Bioinformatics Market 2015-2019 - Rapid Developments in Molecular Diagnostics 2Global Bioinformatics Market 2015-2019 - Rapid Developments in Molecular Diagnostics 3Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 2Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 3Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 4Baxter Ventures, Mayo Clinic And Velocity Pharmaceutical Development Announce The Formation Of Vitesse Biologics, LLC, A Company Structured To Accelerate Therapeutic Innovation 5Epic Sciences Expands Silicon Valley Bank Credit Facility 2Epic Sciences Expands Silicon Valley Bank Credit Facility 3
... a wealth of new information about single-walled carbon nanotubes through ... the American Chemical Society journal ACS Nano features ... Bruce Weisman to understand how the lengths and imperfections of ... light they emit at near-infrared wavelengths. The researchers found ...
... 31, 2012  Soligenix, Inc. (OTCBB: SNGX) (Soligenix or the ... filed a Certificate of Amendment to its Amended and ... split of its common stock which will take effect ... we believe this is an opportune time to effect ...
... Calif., Jan. 31, 2012   Veracyte, Inc ., a ... cytology, today announced the appointment of Mark Spring as ... that Mark Spring has joined the Veracyte team," said ... extensive experience as a CFO and senior finance leader ...
Cached Biology Technology:Perfect nanotubes shine brightest 2Soligenix Announces 1 for 20 Reverse-Split of its Common Stock 2Soligenix Announces 1 for 20 Reverse-Split of its Common Stock 3Soligenix Announces 1 for 20 Reverse-Split of its Common Stock 4Veracyte Appoints Mark Spring as Chief Financial Officer 2Veracyte Appoints Mark Spring as Chief Financial Officer 3
(Date:5/14/2015)... and Markets ( http://www.researchandmarkets.com/research/5whpxg/fingerprint ) has announced ... Smart Mobile Devices " report to their offering. ... watershed year for fingerprint sensors in smartphones and tablets, ... fingerprint sensors a raison d,etre in the mobile milieu ... must-have feature in flagship smartphones. The key ...
(Date:5/11/2015)... 2015  Synaptics Incorporated (NASDAQ: SYNA ), ... announced the appointment of Wajid Ali ... reporting to Rick Bergman , President and ... Officer, Kathleen Bayless , who announced her ... Ali brings extensive financial management expertise to Synaptics, ...
(Date:5/11/2015)... N.Y. , May 11, 2015 Curemark ... announced the start of a new Phase III double ... of its novel formulation, CM-AT, on all children ages ... of its FDA Phase III double blinded clinical trial ... had low levels of the digestive enzyme chymotrypsin. This ...
Breaking Biology News(10 mins):Global Smart Mobile Devices Fingerprint Sensors Market 2015-2019: Key Vendors are Authentec, Validity Sensors, Fingerprint Cards, Next Biometrics Group. IDEX, and Qualcomm 2Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2
... grapes slow what,s for many Americans a downhill sequence of ... and type 2 diabetes? Scientists at the University ... effect of grapes in reducing risk factors related to cardiovascular ... due to phytochemicals -- naturally occurring antioxidants that ...
... know that eating a calcium-rich diet is important for ... clearly on display in any elementary school cafeteria where ... icons encouraging children to make sure they drink milk ... children to pay attention to their dairy intake might ...
... Studies led by Stony Brook University professor of chemistry ... time a drug remains bound to its target, or ... agents. Tonge will present these results at ... meeting in a talk titled "Slow Onset Inhibitors of ...
Cached Biology News:Grapes reduce risk factors for heart disease and diabetes, U-M animal study shows 2Grapes reduce risk factors for heart disease and diabetes, U-M animal study shows 3Study suggests a much earlier onset for bone problems 2Study suggests a much earlier onset for bone problems 3Lengthening time a drug remains bound to a target may lead to improving diagnostics, therapy 2
384 Cluster Tube Racks...
Request Info...
Unique enzyme blend containing Taq and Pwo DNA Polymerase and another thermostable enzyme. The Expand 20 kbPLUS PCR System also includes an optimized reaction buffer, MgCl2 solution, and a human cont...
... The EC105 power supply is a highly compact, ... A single adjustment knob and one hi-lo range ... 10 volt increments from 20 to 250 volts. ... from indicating output voltage to output current. For ...
Biology Products: